Pfizer is paying top dollar for a…
Pfizer is paying top dollar for a GLP-1 candidate from [...]
Pfizer is paying top dollar for a GLP-1 candidate from [...]
The long-planned legislation contains “encouraging steps” but is overall “not [...]
After winning an approval decades in the making last year—and [...]
Clinical guidelines are vague, so we asked psychiatrists what to [...]
Rezolute’s stock has plunged 87% after the company’s rare disease [...]
Eli Lilly has surpassed analysts’ highest hopes for the efficacy [...]
Moderna has tapped Swedish long-acting drug formulation company Nanexa to [...]
Barreling toward the end of its cash runway, GRI Bio [...]
OTR may still be keeping its own pipeline under wraps, [...]
Two affiliates of Apple Tree Partners have filed for bankruptcy, [...]